SALT AND CRYSTAL FORM OF COMPOUND HAVING AGONISTIC ACTIVITY TO S1P5 RECEPTOR

An object of the present invention is to provide a compound with an improved balance of S1P5 receptor agonist activity with respect to S1P1 receptor, and a form suitable for drug substances of pharmaceuticals. Provided is Compound I having high S1P5 receptor-selective agonist activity on the S1P1 re...

Full description

Saved in:
Bibliographic Details
Main Authors FUJITO, Takayuki, BEVILL, Melanie Janelle, JOHNSON, Courtney S, PARENT, Stephan D, HOUSTON, Travis Lee, IMURA, Naoko, KIJIMA, Hideomi, OTANI, Shuhei
Format Patent
LanguageEnglish
Published 28.02.2024
Online AccessGet full text

Cover

More Information
Summary:An object of the present invention is to provide a compound with an improved balance of S1P5 receptor agonist activity with respect to S1P1 receptor, and a form suitable for drug substances of pharmaceuticals. Provided is Compound I having high S1P5 receptor-selective agonist activity on the S1P1 receptor. In addition, the crystal forms of Compound I, the salts of Compound I, and the crystal forms of salts thereof disclosed in the present invention are provided as drug substances of pharmaceuticals.
Bibliography:Application Number: ZA20220001784